247 related articles for article (PubMed ID: 30302637)
1. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.
Choudry MHA; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Dec; 25(13):3950-3959. PubMed ID: 30302637
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Adolescent and Young Adults with Peritoneal Metastases.
Dhir M; Ramalingam L; Shuai Y; Pakrafter S; Jones HL; Hogg ME; Zureikat AH; Holtzman MP; Ahrendt SA; Bahary N; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2017 Apr; 24(4):875-883. PubMed ID: 27995449
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
Ihemelandu C; Mavros MN; Sugarbaker P
Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
[TBL] [Abstract][Full Text] [Related]
4. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
6. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
7. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
8. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
[TBL] [Abstract][Full Text] [Related]
9. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
10. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
11. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
[TBL] [Abstract][Full Text] [Related]
13. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
Schneider MA; Eshmuminov D; Lehmann K
Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
[TBL] [Abstract][Full Text] [Related]
14. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
Robella M; Vaira M; Cinquegrana A; De Simone M
Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
[TBL] [Abstract][Full Text] [Related]
16. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
17. Curative Surgical Resection as a Component of Multimodality Therapy for Peritoneal Metastases from Goblet Cell Carcinoids.
Radomski M; Pai RK; Shuai Y; Ramalingam L; Jones H; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2016 Dec; 23(13):4338-4343. PubMed ID: 27401448
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
19. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis.
Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D
Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928
[TBL] [Abstract][Full Text] [Related]
20. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy.
Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Lee B
Ann Surg Oncol; 2018 Mar; 25(3):688-693. PubMed ID: 29260417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]